Bausch Health Companies Inc. (BHC) News

Bausch Health Companies Inc. (BHC): $7.69

-0.17 (-2.16%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Filter BHC News Items

BHC News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

BHC News Highlights

  • For BHC, its 30 day story count is now at 6.
  • Over the past 23 days, the trend for BHC's stories per day has been choppy and unclear. It has oscillated between 1 and 2.
  • The most mentioned tickers in articles about BHC are EYE and NICE.

Latest BHC News From Around the Web

Below are the latest news stories about BAUSCH HEALTH COMPANIES INC that investors may wish to consider to help them evaluate BHC as an investment opportunity.

Bausch Health to Announce Fourth-Quarter and Full-Year 2022 Results on Feb. 23

Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) will release its fourth-quarter and full-year financial results on Thursday, Feb. 23, 2023. Bausch Health will host a conference call and live webcast at 8:00 a.m. U.S. EST to discuss the results and provide a business update.

Yahoo | February 1, 2023

15 Largest Ophthalmology Companies in the World

In this article, we will take a look at the 15 largest ophthalmology companies in the world. If you want to see more companies in this selection, go to the 5 Largest Ophthalmology Companies in the World. The ophthalmology industry encompasses the diagnosis, treatment, and prevention of eye disorders and diseases. This includes medical and […]

Yahoo | January 31, 2023

7 Retirement Stocks to Buy Now OR You’ll Be Kicking Yourself Later

Consider adding these leading companies to a portfolio that is aimed at getting you to the finish line when it comes to retiring.

Joel Baglole on InvestorPlace | January 24, 2023

Most Active Equity Options For Midday - Monday, Jan. 23

Here are the most active equity options for midday.

TalkMarkets.com | January 23, 2023

12 Most Undervalued Pharma Stocks To Buy According To Hedge Funds

In this article, we discuss 12 most undervalued pharma stocks to buy according to hedge funds. If you want to see more stocks in this selection, check out 5 Most Undervalued Pharma Stocks To Buy According To Hedge Funds. Fitch Ratings has assigned a ‘Neutral’ outlook to the global pharmaceutical and biotech sector, indicating Fitch’s […]

Yahoo | January 23, 2023

Bausch + Lomb Corporation's (NYSE:BLCO) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?

Bausch + Lomb's (NYSE:BLCO) stock is up by a considerable 12% over the past three months. But the company's key...

Yahoo | January 13, 2023

Bausch Health Companies (NYSE:BHC) shareholders are up 19% this past week, but still in the red over the last three years

It's nice to see the Bausch Health Companies Inc. ( NYSE:BHC ) share price up 19% in a week. But the last three years...

Yahoo | January 9, 2023

Implied Volatility Surging for Bausch + Lomb (BLCO) Stock Options

Investors need to pay close attention to Bausch + Lomb (BLCO) stock based on the movements in the options market lately.

Yahoo | December 27, 2022

First tazarotene lotion treatment for acne vulgaris, ARAZLO™ (tazarotene lotion, 0.045%), now available to patients through Quebec, Ontario, Alberta, Saskatchewan and federal NIHB public drug plans

Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC) and its Canadian dermatology division, one of the largest prescription dermatology health care businesses in Canada, today announced that its new topical prescription treatment for acne vulgaris, ARAZLOTM (tazarotene lotion, 0.045% w/w), is now available to patients through the provincial public drug plans of Quebec, Ontario, Alberta and Saskatchewan, as well as the federal government's Non-Insured Health Benefits (NIHB) drug plan, which serves

Yahoo | December 22, 2022

John Paulson Hits the Jackpot With Horizon Buyout — Here Are His 2 Top Stocks Right Now

John Paulson, the billionaire who at the height of the 2007 credit bubble made his fortune from betting against subprime mortgages has hit the jackpot again. As a major investor in Horizon Therapeutics, Paulson is in line for a $500 million payday, given the biotech is to be acquired by Amgen in a $27.8 billion deal. To bring Horizon under the fold, Amgen will pay $116.50 per share in cash. This is 267% higher price than the average of $31 per share paid by Paulson, who has been a Horizon invest

Yahoo | December 14, 2022


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.5864 seconds.